Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11432046 | PMC |
| http://dx.doi.org/10.1056/NEJMc2400751 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial.
J Clin Psychiatry
January 2025
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, and Department of Psychiatry, New York University School of Medicine, New York, New York.
There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor.
View Article and Find Full Text PDFEfficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder: Results of a Phase 2 Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Trial.
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFSafety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity.
Clin Drug Investig
January 2025
Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan.
Background: Anti-obesity medications are recommended for patients who do not achieve and maintain weight loss despite lifestyle interventions. S-309309 is a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 being developed as a treatment for obesity.
Objective: The objective of the study was to investigate the safety, clinical pharmacology, pharmacokinetics and pharmacodynamic biomarker of S-309309.
Perioperative ketamine to reduce and prevent acute and chronic post-thoracotomy pain: a randomized, double-blind, placebo-controlled clinical trial.
J Thorac Dis
December 2024
Department of Anaesthesiology, Critical Care and Pain Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.
Background: Moderate to severe postoperative pain is common among patients following thoracotomy and serves as a risk factor for developing chronic post-thoracotomy pain (CPTP). This randomized controlled trial evaluated the effects of pre-emptively administered ketamine compared to placebo and standard care on both acute postoperative pain and CPTP.
Methods: Two hundred patients were enrolled in this prospective, randomized trial.
Effectiveness of Distant/Remote Blessing Treatment on Cognitive-motor Function: A Randomized Double-blind Placebo-controlled Trial.
Health Psychol Res
January 2025
Trivedi Science Research laboratory Pvt Ltd.
Background: Biofield therapies can be administered in person (hands-on treatment) or remotely, and this study focuses on the latter. A literature review did not find any reports on the effectiveness of remote biofield energy /blessing therapy in enhancing cognition and motor function performance in adults.
Objective: The aim of this study was to examine the effect of distant/remote blessing (biofield energy) therapy on the cognitive and motor functions in adults with self-reported neuropsychological impairments using NIH Toolbox.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!